SAM
AGIO icon

Silvercrest Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Silvercrest Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-82,679
Closed -$2.75M – 828
2025
Q2 		$2.75M Hold
82,679
– – 0.02% 510
2025
Q1 		$2.42M Sell
82,679
-478
-0.6% -$15.9K 0.02% 516
2024
Q4 		$2.73M Buy
83,157
+3,272
+4% +$154K 0.02% 493
2024
Q3 		$3.55M Buy
+79,885
New +$3.63M 0.02% 422

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Silvercrest Asset Management's AGIO Position: Q3 2025 in Review

Silvercrest Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2025, closing a stake of 82,679 shares — an estimated $2.75M sold.

Silvercrest Asset Management first reported a position in AGIO in Q3 2024 and held it in 4 quarters. The position peaked at $3.55M in Q3 2024. 221 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

  • Silvercrest Asset Management reported no remaining Agios Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Silvercrest Asset Management sold 82,679 Agios Pharmaceuticals shares in Q3 2025, an estimated $2.75M.
  • Silvercrest Asset Management first reported a position in Agios Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Silvercrest Asset Management's Agios Pharmaceuticals position peaked at $3.55M in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on Silvercrest Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.